Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Interpreting Pharmacogenetic Data in the Developing Neonate: The Challenge of Hitting a Moving Target

5 Sept 2012

Abstract excerpt

In a 2010 review in Clinical Pharmacology & Therapeutics, Nick Holford noted that in neonates and young infants, maturation of the organs responsible for drug clearance is a more important determinant of pharmacokinetics (PK) than is body size.(1) Here we review recent developments that provide new insights into how physiological and environmental changes associated with adaptation to extrauterine life affect the...

Topics

Join the communities discussing this publication.

Ion Transport and Channel Regulation
Pharmaceutical studies and practices
Pharmacogenetics and Drug Metabolism

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 22948896
DOI: 10.1038/clpt.2012.130

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interpreting Pharmacogenetic Data in the Developing Neonate: The Challenge of Hitting a Moving TargetPMID 22948896Read ↗

Ontogeny and drug metabolism in newbornsSemantic proximity Read ↗

Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children.Semantic proximity Read ↗

Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children.Semantic proximity Read ↗

Ontogeny of Phase I Metabolism of DrugsSemantic proximity Read ↗

Meta‐analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modelingSemantic proximity Read ↗

Developmental pharmacogenetics: a general paradigm for application to neonatal pharmacology and toxicology.Semantic proximity Read ↗

Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug.Semantic proximity Read ↗

Development and Evaluation of Ontogeny Functions of the Major UDP‐Glucuronosyltransferase Enzymes to Underwrite Physiologically Based Pharmacokinetic Modeling in Pediatric PopulationsSemantic proximity Read ↗

Metronidazole Metabolism in Neonates and the Interplay Between Ontogeny and Genetic Variation.Semantic proximity Read ↗

Phenotyping of drug metabolism in infants and children: potentials and problems.Semantic proximity Read ↗

Ontogeny of Hepatic Transporters and Drug-Metabolizing Enzymes in Humans and in Nonclinical SpeciesSemantic proximity Read ↗

Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.